Pfizer Inc Q3 2023 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Trung Chuong Huynh - UBS Investment Bank, Research Division - Analyst : I have one on flu and then just one on danu. So on flu, can you confirm the comparator in the 18 to 64 and also the 64 age groups was the low dose flu vaccines? Is there a risk FDA is going to need data against high-dose flu vaccines? And from a commercial perspective, do you think you still need high dose flu data, the comparator against high-dose flu data, given that's what's recommended by CDC in the older population? And then on danu, should we just -- just on the data that we expect before year-end, what do you need to show in that in order to move it into Phase 3 trials? Is something similar to the Phase 2 we saw earlier this year enough to move it to Phase 3?

Question: Kerry Ann Holford - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : Two questions on vaccines, please. Turning to RSV, in August, GSK filed a lawsuit against Pfizer alleging patent infringement. So I wonder if you could just talk to the next steps here, perhaps a time line that you anticipate for this. And should we think that this could ultimately result in some form of royalty payments from PFE to GSK? And then on Penbraya, how does the recent ACIP recommendation sit against your expectations for the sales ramp and peak potential for this vaccine? If the vaccine is effectively only used for dose 2 of 3, does that significantly reduce the commercial opportunity you had anticipated for the vaccine?